Current Headlines

  1. Aastrom Biosciences Acquires Sanofi Cell Therapy And Regenerative Medicine Business

    Aastrom Biosciences announced that it has signed a definitive agreement to acquire Sanofi’s Cell Therapy and Regenerative Medicine (CTRM) business for $6.5 million.

  2. Researchers Identify Astrocytes’ New Role In Neuronal Communication

    Scientists from the University of California, Los Angeles, found that brain cells called astrocytes might play a part in neuronal communication only during bursts of neuron activity.

  3. Biomarker Leads To Cancer Drug Resistance And Tumor Formation

    Researchers from the University of California, San Diego School of Medicine have identified CD61, a biomarker present on the surface of drug-resistant tumors, which they believe could shed light on why many drugs used in the treatment of lung, breast, and pancreatic cancer also encourage drug resistance and eventually lead to tumor formation in patients.

  4. NSTDA Discovers New Anti-Malaria Drug

    Thailand’s state run National Science and Technology Development Agency, or NSTDA, has developed a new medication for malaria that will soon be tested in clinical trials. The medication, a chemical called P218, was designed to target the malarial enzyme and stop the disease’s DNA from replicating. Researchers have said that the drug can completely destroy malaria parasites, and it won’t be expensive for the country to manufacture.

  5. Sarepta Therapeutics To File NDA For Muscular Dystrophy Drug

    Sarepta Therapeutics, a company focused on developing RNA-based treatments, announced its intent to file a New Drug Application for eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) by the end of 2014.

  6. Researchers To Test Drugs On Micro-Organs Instead Of Mice

    Researchers from the Vanderbilt University Medical Center in Nashville, Tennessee, are developing miniaturized living copies of human organs to advance research in drug testing.


  7. Genoa’s Inhaled Pirfenidone Shows Potential in Lung Fibrosis

    Genoa Pharmaceuticals and collaborators Martin Kolb and Kjetil Ask at McMaster University announced additional measured advantages of inhaled GP-101 (aerosol pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF).

  8. Emergent BioSolution’s BioThrax Receives FDA Orphan Drug Designation

    Emergent BioSolutions announced in a press release that the Food and Drug Administration (FDA) has granted BioThrax an Orphan Drug Designation.

  9. Beckman Coulter Life Sciences To Acquire Cytometer Maker Xitogen

    Beckman Coulter Life Sciences has entered into an agreement to acquire Xitogen Technologies Inc. together with Cytojene Corporation. Xitogen, a flow cytometer developer based in Suzhou and Dalian, China, will provide Beckman Coulter Life Sciences with both a strong operational base in the growing China market and a high quality research instrument to round out their world-class cytometry offering.

  10. TB Drug May Fight Other Diseases Yet Avoid Resistance

    Chemists from the University of Illinois are studying a new multi-targeted tuberculosis drug that could treat other diseases and yet avoid resistance.